

## ASX ANNOUNCEMENT MARKET RELEASE

25 July 2023

### RESCHEDULED INVESTOR CALL

---

**Perth, Western Australia** - Australian medical device, digital health technology company, Artrya Limited (ASX: AYA) (Artrya or the Company) advises that it will be holding a rescheduled investor call to discuss the Quarterly Q4 FY23 results and provide an update at 10:00am AEST (8:00am AWST) Thursday, 27 July 2023.

Due to an incorrect meeting link in the Quarterly Activity Report issued Monday, 24 July, Artrya has chosen to reschedule the investor call. We sincerely apologise for any inconvenience caused but felt it best to postpone the meeting to allow for as many valued shareholders as possible to join.

Join the conference call on Zoom using the following link.

<https://bellpotter.zoom.us/j/85658021816?pwd=aFRCcTQ0dzc0cmliSHI3VXRURUWVtUT09>

Meeting ID: 856 5802 1816

Passcode: 222753

*This announcement was approved by the CEO.*

---

#### For further information please contact:

Investor Enquiries:  
Mathew Regan  
Artrya Limited  
+61 427 477 298  
[investors@artrya.com](mailto:investors@artrya.com)

#### About Artrya

Based in Perth, Western Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA). Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary artery disease and develop a holistic overview of a patient at risk. Artrya has developed deep learning algorithms that will streamline how medical care for heart disease is delivered. Artrya USA Inc. is a wholly owned subsidiary of Artrya Limited.

For more information, see [www.artrya.com](http://www.artrya.com)